InvestorsHub Logo
Followers 7
Posts 566
Boards Moderated 0
Alias Born 12/03/2013

Re: None

Tuesday, 11/25/2014 3:56:29 AM

Tuesday, November 25, 2014 3:56:29 AM

Post# of 48316
Dr. Alain Algazi and Supported by OncoSec and Merck Will Evaluate Combination of KEYTRUDA® and ImmunoPulse in Metastatic Melanoma

...

This Phase II clinical trial will be conducted as a multicenter Investigator Sponsored Trial (IST), with UCSF and Dr. Alain Algazi as the sponsor. Merck will supply pembrolizumab, and OncoSec will provide electroporation devices and plasmid IL-12. Enrollment is expected to begin in Q1 2015.